Tags

Type your tag names separated by a space and hit enter

[Resistance in influenza viruses].
Tidsskr Nor Laegeforen. 2008 Nov 20; 128(22):2601-6.TN

Abstract

BACKGROUND

Influenza virus infection can be prevented and treated with antiviral drugs. The usage of such drugs in Norway has been infrequent, however, they are an important component in our pandemic preparedness planning, as it will probably be difficult to get access to the appropriate vaccine in time before the pandemic reaches the country. The first generation of influenza drugs acquired resistance to a large degree, in contrast to the modern neuraminidase inhibitors that until recently have had minor problems with resistance.

MATERIAL AND METHODS

This review is based on research found in relevant published literature, together with experience from a virology reference laboratory and participation in a national and international surveillance including susceptibility testing.

RESULTS AND INTERPRETATION

While resistance has been a longstanding problem with the use of the "old" influenza drugs amantadine and rimantadine, only during the winter 2007/2008 did it become clear, that a certain type of virus acquired widespread resistance against the neuraminidase inhibitor oseltamivir. Resistance surveillance is crucial for the correct choice of empiric treatment for influenza infection, and will be one of the most important tasks at the National Influenza Centre in certain phases of a pandemic. The current situation with an increasing resistance problem strengthens the need to conduct continuous monitoring of antiviral susceptibility, as well as development of new antiviral drugs and treatment regimes.

Authors+Show Affiliations

Avdeling for virologi, Nasjonalt folkehelseinstitutt, Postboks 4404 Nydalen, 0403 Oslo. olav.hungnes@fhi.noNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

nor

PubMed ID

19023375

Citation

Hungnes, Olav, and Susanne Gjeruldsen Dudman. "[Resistance in Influenza Viruses]." Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke, vol. 128, no. 22, 2008, pp. 2601-6.
Hungnes O, Dudman SG. [Resistance in influenza viruses]. Tidsskr Nor Laegeforen. 2008;128(22):2601-6.
Hungnes, O., & Dudman, S. G. (2008). [Resistance in influenza viruses]. Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke, 128(22), 2601-6.
Hungnes O, Dudman SG. [Resistance in Influenza Viruses]. Tidsskr Nor Laegeforen. 2008 Nov 20;128(22):2601-6. PubMed PMID: 19023375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Resistance in influenza viruses]. AU - Hungnes,Olav, AU - Dudman,Susanne Gjeruldsen, PY - 2008/11/22/pubmed PY - 2008/12/17/medline PY - 2008/11/22/entrez SP - 2601 EP - 6 JF - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke JO - Tidsskr. Nor. Laegeforen. VL - 128 IS - 22 N2 - BACKGROUND: Influenza virus infection can be prevented and treated with antiviral drugs. The usage of such drugs in Norway has been infrequent, however, they are an important component in our pandemic preparedness planning, as it will probably be difficult to get access to the appropriate vaccine in time before the pandemic reaches the country. The first generation of influenza drugs acquired resistance to a large degree, in contrast to the modern neuraminidase inhibitors that until recently have had minor problems with resistance. MATERIAL AND METHODS: This review is based on research found in relevant published literature, together with experience from a virology reference laboratory and participation in a national and international surveillance including susceptibility testing. RESULTS AND INTERPRETATION: While resistance has been a longstanding problem with the use of the "old" influenza drugs amantadine and rimantadine, only during the winter 2007/2008 did it become clear, that a certain type of virus acquired widespread resistance against the neuraminidase inhibitor oseltamivir. Resistance surveillance is crucial for the correct choice of empiric treatment for influenza infection, and will be one of the most important tasks at the National Influenza Centre in certain phases of a pandemic. The current situation with an increasing resistance problem strengthens the need to conduct continuous monitoring of antiviral susceptibility, as well as development of new antiviral drugs and treatment regimes. SN - 0807-7096 UR - https://www.unboundmedicine.com/medline/citation/19023375/[Resistance_in_influenza_viruses]_ L2 - http://tidsskriftet.no/article/1769388 DB - PRIME DP - Unbound Medicine ER -